AU5093593A - Inhibition of tumor metastasis via neutralization of tissue factor function - Google Patents

Inhibition of tumor metastasis via neutralization of tissue factor function

Info

Publication number
AU5093593A
AU5093593A AU50935/93A AU5093593A AU5093593A AU 5093593 A AU5093593 A AU 5093593A AU 50935/93 A AU50935/93 A AU 50935/93A AU 5093593 A AU5093593 A AU 5093593A AU 5093593 A AU5093593 A AU 5093593A
Authority
AU
Australia
Prior art keywords
inhibition
tissue factor
tumor metastasis
factor function
metastasis via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50935/93A
Inventor
Thomas S. Edgington
Barbara M Mueller
Ralph A. Reisfeld
Wolfram Ruf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU5093593A publication Critical patent/AU5093593A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU50935/93A 1992-08-28 1993-08-27 Inhibition of tumor metastasis via neutralization of tissue factor function Abandoned AU5093593A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93679292A 1992-08-28 1992-08-28
US936792 1992-08-28
PCT/US1993/008047 WO1994005328A1 (en) 1992-08-28 1993-08-27 Inhibition of tumor metastasis via neutralization of tissue factor function

Publications (1)

Publication Number Publication Date
AU5093593A true AU5093593A (en) 1994-03-29

Family

ID=25469083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50935/93A Abandoned AU5093593A (en) 1992-08-28 1993-08-27 Inhibition of tumor metastasis via neutralization of tissue factor function

Country Status (2)

Country Link
AU (1) AU5093593A (en)
WO (1) WO1994005328A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6004554A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
AU702250B2 (en) * 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
ES2231817T3 (en) 1995-06-07 2005-05-16 Ortho-Mcneil Pharmaceutical, Inc. ANTI-FABRIC ANTIBODIES INTRODUCED TO CDR AND PROCEDURES FOR THE SAME USE.
CN100333796C (en) * 1997-01-22 2007-08-29 德克萨斯州立大学董事会 Tissue factor methods and compositions for coagulation and tumor treatment
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
DE19719652A1 (en) * 1997-05-09 1998-12-03 Merckle Gmbh Use of tissue factor
US6930094B1 (en) 1997-05-09 2005-08-16 Merckle Gmbh Tissue factor for influencing blood vessel formation
JP2001510168A (en) * 1997-07-18 2001-07-31 ノボ ノルディスク アクティーゼルスカブ Use of FVIIa or FVIIai for the treatment of adverse conditions associated with FVIIa-mediated intracellular signaling pathway
US6461610B1 (en) 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
CA2325346A1 (en) 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
AU2371400A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CN1356913A (en) 1998-12-18 2002-07-03 杜邦药品公司 Vitronectic receptor antagonist pharmaceuticals
US6608066B1 (en) 1999-10-27 2003-08-19 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
EP1829535A3 (en) * 1999-10-27 2007-10-24 Tanox, Inc. Tissue factor antagonists and methods of use thereof
EP1260817A3 (en) 2001-05-08 2002-12-18 Warner-Lambert Company Method for direct measurement of coagulation factor VIIa activity in plasma
AU2002350623A1 (en) 2001-10-26 2003-05-06 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
AU2002336920A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
DK2298347T3 (en) 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
BRPI0410875A (en) * 2003-05-30 2006-07-04 Centocor Inc Tumor Factor Growth Inhibition Method
CA2628238A1 (en) * 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
WO2008054822A2 (en) * 2006-11-03 2008-05-08 Angiogen Llc Compositions comprising alternatively spliced tissue factor (as tf) and methods for use
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
SI2582728T1 (en) * 2010-06-15 2018-01-31 Genmab A/S Human antibody drug conjugates against tissue factor
US8722044B2 (en) * 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
WO2015075201A1 (en) * 2013-11-21 2015-05-28 Genmab A/S Antibody-drug conjugate lyophilised formulation
JP5957637B2 (en) * 2014-02-03 2016-07-27 国立研究開発法人国立がん研究センター Anti-TissueFactor monoclonal antibody
WO2018036117A1 (en) * 2016-08-22 2018-03-01 复旦大学 Antibody targeted to tissue factor, preparation method therefor, and use thereof
CN106938051B (en) * 2016-08-22 2019-10-11 复旦大学 Target the antibody-drug conjugates of tissue factor
BR112020013679A2 (en) * 2018-01-04 2020-12-01 Iconic Therapeutics, Inc. antitecid factor antibodies, antibody-drug conjugates and related methods
CN107929737A (en) * 2018-01-15 2018-04-20 福州大学 A kind of pharmaceutical composition of anti-tumor metastasis and its application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system

Also Published As

Publication number Publication date
WO1994005328A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
AU5093593A (en) Inhibition of tumor metastasis via neutralization of tissue factor function
AU5788396A (en) Methods of inhibition or killing of cancer cells
AU639192B2 (en) Treatment of water
EP0690673A4 (en) Systemic gene treatment of connective tissue diseases
HU9300536D0 (en) Compounds of medical effect
AU2265895A (en) Inhibition of liver cancer by the use of gnrh and gnrh analogs
GB9512290D0 (en) Uses of polyhexanide
AU3808289A (en) Pharmaceutical compositions for the inhibition of tumor metastasis
IL101410A0 (en) Formulation for the treatment of cancer
AU4382693A (en) Therapeutic uses of pungent botanicals and their related compounds
AU2479695A (en) Prevention of tumor metastasis
ZA935347B (en) Treatment of solid material
AU4133693A (en) Surface treatment of refractories
AU2548095A (en) Human inhibitor of apoptosis gene 1
AU1339292A (en) Enzymatic treatment of all wall fragments
GB9226258D0 (en) Treatment of water
EP0572563A4 (en) Treatment of esophageal cancer
ZA936166B (en) Methods of treating cancer
AU3641993A (en) Treatment chamber
GB9206079D0 (en) Treatment of water
AU4417996A (en) Treatment of prostate cancer
AU6171196A (en) Therapeutic uses of ta99
AU3380793A (en) Treatment of waste or other material
AU4825993A (en) New compounds for use in the treatment of cancer
AU3964093A (en) Novel use of nitroimidazoles